David Shulman
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Shulman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:22 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06709495 · Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory SarcomasDavid S Shulman, MD · recruiting · Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor · principal investigator
- Ph2NCT04129151 · Palbociclib + Ganitumab In Ewing SarcomaDana-Farber Cancer Institute · terminated · Ewing Sarcoma, Ewing's Sarcoma Recurrent · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Validation and implementation of ctDNA as a clinically informative biomarkerin AYAs with sarcomas.K08CA290061 · NCI · DANA-FARBER CANCER INST · fiscal years 2024 to 2026 · $253,592 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in ewing sarcoma, ranked by citations from NIH iCite, fetched 2026-11-12 08:22 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed